EHA 2023 | MajesTEC-2 update: teclistamab plus lenalidomide in R/R multiple myeloma
Carlyn Tan, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, summarizes the key findings of the Phase Ib MajesTEC-2 study (NCT04722146) which investigated the combination of teclistamab with standard of care therapies, including lenalidomide, for patients with relapsed/refractory (R/R) triple-class exposed (TCE) multiple myeloma. Dr Tan highlights the favorable safety profile and efficacy of the teclistamab and lenalidomide combination, with toxicity rates consistent with the MajesTEC-1 (NCT04557098) trial that evaluated teclistamab alone. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen – research funding, advisory board
Sanofi – advisory board
Takeda – research funding
